|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.090 USD | +1.95% |
|
+5.03% | +16.11% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +436.59% | 2 | |||||
| 1,215.79 | +4.72% | 29 | ||||||
| 252.87 | +6.1% | 23 | ||||||
| 253.55 | +12.8% | 29 | ||||||
| 360.76 | +10.9% | 17 | ||||||
| 129.74 | +7.44% | 27 | ||||||
| 220.95 | +21.97% | 21 | ||||||
| 154.88 | +1.93% | 21 | ||||||
| 311.78 | +10.34% | 23 | ||||||
| 352.5 | -0.44% | 30 | ||||||
| 157.83 | +25.39% | 29 | ||||||
| 29.19 | +11.53% | 27 | ||||||
| 63.08 | +10.86% | 25 | ||||||
| 548.69 | +23.29% | 29 | ||||||
| 96.92 | +27.03% | 23 | ||||||
| 20.77 | +5.82% | 19 | ||||||
| 9,973.33 | +34.27% | 15 | ||||||
| 6,136.87 | +21.93% | 15 | ||||||
| 81.26 | +72.98% | 16 | ||||||
| 49.47 | +38.23% | 19 | ||||||
| Average | 1,021.06 | +39.18% | 22 | ||||||
| Weighted average by Cap. | 674.71 | +11.00% | 25 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
